Stem cell therapy is legal in the United States, but only a narrow set of treatments have full FDA approval. The vast majority of stem cell procedures marketed by private clinics operate in a legal gray area or are flatly illegal under federal law. Understanding the difference between approved and unapproved treatments is essential, because hundreds of clinics across the country advertise stem cell injections for conditions like joint pain, neurological disease, and anti-aging without the regulatory clearance required to do so.
What the FDA Actually Approves
The FDA has approved roughly a dozen stem cell-based products, and nearly all of them are cord blood preparations used for blood disorders and certain cancers. These products, made from donated umbilical cord blood, contain blood-forming stem cells that can rebuild a patient’s blood and immune system after chemotherapy or radiation. Brand names include Hemacord, Allocord, Ducord, and several others produced by university medical centers and blood banks. A newer product called Omisirge, approved for adults and children, expands cord blood cells in a lab before transplant to speed recovery.
Bone marrow transplants, which have been performed for decades, also use stem cells and are well-established in mainstream medicine. Beyond these blood-related uses, no stem cell product has received FDA approval for orthopedic injuries, neurological conditions, cosmetic purposes, or chronic pain. If a clinic tells you their stem cell injection is “FDA approved” for knee arthritis or back pain, that claim is false.
The Legal Line Between Tissue and Drug
Federal law draws a critical distinction that determines whether a stem cell product needs full FDA approval or can be used with lighter oversight. A human cell or tissue product can skip the formal drug approval process only if it meets all four of these criteria: the cells are minimally manipulated (their basic biological characteristics haven’t been altered), used for the same function they perform naturally in the body (called “homologous use”), not combined with other substances beyond basic preservatives, and either used in the same patient they came from or in a close blood relative.
A simple example that passes this test: a skin graft taken from one part of your body and placed on another. The tissue is doing the same job it always did, and it hasn’t been significantly processed. An example that fails: extracting fat tissue, breaking it down through enzymatic digestion to isolate stem cells, then injecting those cells into a damaged knee. The removed tissue (fat) and the implanted product (isolated cells) are not the same thing, and the processing changes the tissue’s characteristics.
This distinction matters because many clinics offering same-day stem cell procedures claim they’re simply returning your own cells to your body. Federal courts have rejected that argument repeatedly.
Court Rulings That Settled the Debate
Two major federal appeals court decisions have confirmed the FDA’s authority to regulate these treatments as drugs. In 2021, the Eleventh Circuit ruled in United States v. US Stem Cell Clinic that a procedure extracting stem cells from body fat and re-injecting them did not qualify for the “same surgical procedure” exception that some clinics relied on. The court held that the exception only applies when the removed tissue and the implanted tissue are in their original form, not after extensive processing.
In September 2024, the Ninth Circuit reached the same conclusion in United States v. California Stem Cell Treatment Center. The court ruled that stromal vascular fraction, a stem cell mixture derived from fat tissue, constitutes a “drug” under federal law. Because the clinic removed fat but implanted a processed cell product, the two were not the same tissue, and the procedure required FDA oversight. These rulings effectively closed the legal loophole that many clinics had been operating under.
How Clinics Get Into Legal Trouble
The FDA issues warning letters to clinics that manufacture and distribute unapproved stem cell products. Common violations include selling umbilical cord blood products without approval, failing to follow basic manufacturing safety standards, using products for purposes that don’t match the tissue’s natural function, and skipping required donor screening. The agency has documented serious adverse events tied to unapproved products, including infections, hospitalizations, and patient deaths. One reported death involved a patient who self-injected an imported placental tissue product that the FDA had never approved.
The Federal Trade Commission also pursues clinics for deceptive advertising. In January 2025, the FTC and the state of Georgia obtained a judgment of more than $5.1 million against the co-founders of the Stem Cell Institute of America. The court found the company had created false advertisements claiming stem cell injections were effective for osteoarthritis, neuropathy, joint pain, and other conditions without adequate evidence. Both founders were permanently banned from marketing any regenerative medicine treatments. The company had also trained other clinics nationwide to use the same deceptive marketing playbook, including hosting free “educational seminars” designed to recruit patients.
State Laws That Push the Boundaries
While federal law sets the baseline, a handful of states have passed legislation that expands access to unproven stem cell treatments. Texas, North Carolina, Mississippi, and Utah have enacted laws that go beyond the federal “Right to Try” framework. Federal Right to Try laws allow terminally ill patients to access experimental treatments that have completed initial safety testing. These state laws extend that access to patients with “severe chronic diseases,” a category left open to broad interpretation that could include conditions ranging from obesity to multiple sclerosis.
These state laws create a complicated situation. A clinic operating under a state experimental access law may still be violating federal regulations if the stem cell product hasn’t gone through the FDA’s investigational process. The practical result is a patchwork where some states actively promote treatments that federal agencies consider unapproved and potentially unsafe.
What It Takes to Run a Legal Clinical Trial
Clinics that want to study a new stem cell therapy legally must file an Investigational New Drug application with the FDA. This application requires preclinical safety data (typically from animal studies), detailed manufacturing information proving the product can be made consistently and safely, and a clinical protocol reviewed by an independent ethics board. After submission, the FDA has 30 days to review the application before any patient can be treated.
This process exists for a reason: it ensures that patients in early trials aren’t exposed to unreasonable risks. Clinics that charge patients for stem cell treatments outside of this framework are bypassing the safety checks that legitimate researchers follow. If a clinic is offering a stem cell treatment that isn’t one of the approved cord blood products or bone marrow transplants, and it isn’t part of a registered clinical trial, the treatment is almost certainly being administered without proper FDA authorization.
How to Tell If a Treatment Is Legitimate
You can search for registered clinical trials at ClinicalTrials.gov to verify whether a clinic’s stem cell treatment is part of an authorized study. Legitimate trials have an NCT identification number and are reviewed by an institutional review board. They do not typically charge patients thousands of dollars for the experimental treatment itself.
Red flags include clinics that advertise stem cell therapy for a long list of unrelated conditions, charge large fees upfront, claim their treatment is “FDA approved” for joint or neurological conditions, or pressure you to act quickly. The FDA maintains a list of approved cellular and gene therapy products on its website, which you can check directly. Any product not on that list requires either an active clinical trial authorization or it is being marketed illegally.